
**UPDATES TO SHAREHOLDERS ON PROCEEDINGS COMMENCED BY WEIXIN HOSPITAL
INVESTMENT MANAGEMENT (SHANGHAI) CO. LTD.**

The Board of Directors ("Board") of OUE Lippo Healthcare Limited ("Company") refers to the Company's announcement dated 22 February 2017, wherein the Company announced that there were 2 pending claims by Gao Xin and Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理（上海）有限公司) ("**Weixin**").

The Company announced on 21 September 2017 that it prevailed in the case filed by Gao Xin, and that Gao Xin's appeal against the first instance decision was dismissed.

The Board wishes to update the Company's shareholders on the proceedings brought by Weixin, which is a company controlled by one Mr David Lin Kao Kun ("**Mr David Lin**"), against the Company's subsidiaries, Shanghai Yi Lin Medical Management Consulting Co., Ltd (上海医霖医疗管理咨询有限公司) ("**Shanghai Yilin**") and Wuxi New District Phoenix Hospital Co., Ltd (无锡新区凤凰医院有限责任公司) ("**Wuxi Co.**") before the Shanghai Courts.

In these proceedings, Weixin had sought an order for Shanghai Yilin to transfer the shares in Wuxi Co. to Weixin. Amongst other things, Weixin alleged that this was to give effect to an alleged share transfer agreement between Shanghai Yilin and Weixin, as well as an alleged commitment letter provided by the then-shareholder and legal representative of Shanghai Yilin which purportedly recognized Mr David Lin as the beneficial investor for Wuxi Co. and Shanghai Yilin.

The Company has been notified by its PRC Counsel today that the Shanghai Courts had rendered a first instance judgment in favour of Weixin ("**PRC Judgment**") on or around 13 December 2017.

The Company has also been advised by its PRC Counsel that there is a good chance that the PRC Judgment will be reversed on appeal. The Company's PRC Counsel has further advised that once the appeal against the PRC Judgment is filed, the PRC Judgment will have no effect and Weixin will not be able to enforce the PRC Judgment.

The Company has given instructions to its PRC Counsel to file and vigorously prosecute the appeal.

The Board will make further announcements to update the Company's shareholders as and when there are material developments in the abovementioned proceedings.

By Order of the Board

Dr Wong Weng Hong
Chief Executive Officer and Executive Director
20 December 2017

*This announcement has been prepared by OUE Lippo Healthcare Limited (formerly known as International Healthway Corporation Limited) (the "**Company**") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809 T: +65 6578 9188 F: 64794647 www.ouelh.com